Several lympholytic and cytotoxic agents are used in acute lymphoblastic leukemia (ALL) polychemotherapy.
Genetic variants for cellular components involved in the pharmacokinetics and pharmacodynamics of these drugs can influence
the pharmacological response, and molecular characterization of these genetic variants could be helpful for the
comprehension of the mechanisms of resistance or increased sensitivity. The purpose of this review is to carry out an update
of recent publications on genes that might influence ALL treatment in terms of outcome and/or toxicity and to underlie
the role of genetic variants, particularly single nucleotide polymorphisms (SNP), in predicting clinical response, with
particular reference to the current protocol for ALL therapy used in Italy, AIEOP-BFM ALL 2009.
Keywords: Acute lymphoblastic leukemia, chemotherapy, pharmacogenetics.
Rights & PermissionsPrintExport